 |
|
|
| |
Efficacy of MK-8591 Against Diverse HIV-1 Subtypes and NRTI-Resistant Clinical Isolates
|
| |
| |
Reported by Jules Levin
HIV Drug Therapy, Glasgow 2018, October 28-31, 2018, Glasgow
J.A. Grobler; Q. Huang;D.J. Hazuda; M.-T. Lai
Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
